Research programme: joint and arthritic disorder therapeutics - Seikagaku Corporation
Latest Information Update: 20 Oct 2010
At a glance
- Originator Seikagaku Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Arthritis; Joint disorders